What is NDC 31722-312?

31722-312 is the product NDC for Cisatracurium Besylate, Cisatracurium besylate 10 mg/mL injection, listed with the FDA by Camber Pharmaceuticals Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Camber Pharmaceuticals Inc., NDC labeler code 31722. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Cisatracurium Besylate?

34 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Cisatracurium Besylate NDC 31722-312

NDC codes

FDA NDC Directory

Product NDC (as listed)31722-312Labeler and product segments. Claims need a package NDC.

Product NDC at billing width31722-0312Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
31722-312-10	3172203121031722031210	10 VIAL, SINGLE-DOSE in 1 CARTON (31722-312-10) / 20 mL in 1 VIAL, SINGLE-DOSE (31722-312-02)Marketed from May 4, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cisatracurium Besylate
Generic name (nonproprietary): cisatracurium besylate
Active ingredients: Cisatracurium besylate — 10 mg/mL
Dosage form: Injection
Route: Intravenous
Labeler: Camber Pharmaceuticals Inc.NDC labeler code 31722
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212432
Marketing start: May 4, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Neuromuscular Nondepolarizing Blockade (Physiologic effect)
Identifiers: Product ID 31722-312_da5bd5ef-99b7-449c-8b59-bb9eb2540d62SPL ID da5bd5ef-99b7-449c-8b59-bb9eb2540d62SPL set ID d8b5eb77-b393-4cd7-86c5-d2a9d131f96dRxCUI 199211, 199212, 1730194UNII 80YS8O1MBSUPC 0331722314107, 0331722313025, 0331722313100, 0331722312103, 0331722314022, 0331722312028
Pharmacologic class: Nondepolarizing Neuromuscular Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N431722031210 followed by a unit qualifier and the quantity

Package 31722-0312-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 30, 2026.

Indications (excerpt from the label)

Cisatracurium besylate injection is indicated: •as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age •to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the ICU •to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older Limitations of Use Cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. Cisatracurium besylate injection is a nondepolarizing neuromuscular blocker indicated: as an adjunct to general anes…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 31722-312

What is NDC 31722-312?: 31722-312 is the product NDC for Cisatracurium Besylate, Cisatracurium besylate 10 mg/mL injection, listed with the FDA by Camber Pharmaceuticals Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Cisatracurium Besylate.
What is the active ingredient?: Cisatracurium besylate.
Who is the labeler?: Camber Pharmaceuticals Inc., NDC labeler code 31722. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Cisatracurium Besylate?: 34 other product NDCs are listed under this name. See all Cisatracurium Besylate NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Cisatracurium Besylate NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Cisatracurium Besylate	Cisatracurium besylate 10 mg/mL	Injection, SolutionIntravenous	Avenacy, LLC	83634-655	83634-0655-20
Cisatracurium Besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Camber Pharmaceuticals Inc.	31722-313	31722-0313-10
Cisatracurium Besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Camber Pharmaceuticals Inc.	31722-314	31722-0314-10
Cisatracurium besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Gland Pharma Limited	68083-486	68083-0486-01
Cisatracurium besylate	Cisatracurium besylate 10 mg/mL	InjectionIntravenous	Gland Pharma Limited	68083-487	68083-0487-01
Cisatracurium besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Gland Pharma Limited	68083-488	68083-0488-01
Cisatracurium Besylate	Cisatracurium besylate 10 mg/mL	InjectionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9160	00143-9160-10
Cisatracurium Besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9397	00143-9397-10
Cisatracurium besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Caplin Steriles Limited	65145-135	65145-0135-0165145-0135-10
Cisatracurium besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Caplin Steriles Limited	65145-136	65145-0136-0165145-0136-10

All 35 Cisatracurium Besylate NDCs

Other NDCs under ANDA 212432

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212432
Product	Strength	Form · route	Labeler	Product NDC
Cisatracurium Besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Camber Pharmaceuticals Inc.	31722-313
Cisatracurium Besylate	Cisatracurium besylate 2 mg/mL	InjectionIntravenous	Camber Pharmaceuticals Inc.	31722-314